Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q3
- 저널
- JOURNAL OF KOREAN MEDICAL SCIENCE25(11) · pp.1601 · 2010
- 피인용
- Web of Science 3KCI 1
- JCR IF
- JCR 2009 0.838
- ISSN
- 1011-8934
저자
- 조정선제1저자가톨릭대학교
- 허성호가톨릭대학교
- 백주열가톨릭대학교
- 박만원가톨릭대학교
- 김형두가톨릭대학교
- 정명호전남대학교
- 안영근전남대학교
- 채성철경북대학교
- 허승호계명대학교
- 홍택종부산대학교
- 김영조영남대학교
- 성인환충남대학교
- 채제건전북대학교
- 류재영전주예수병원
- 채인호서울대학교
- 박승정울산대학교
- 배장호건양대학교
- 나승운고려대학교
- 김종진경희대학교
- 최동훈연세대학교
- 장양수연세대학교
- 윤정한연세대학교
- 정욱성가톨릭대학교
- 조정관전남대학교
- 승기배가톨릭대학교
- 조명찬충북대학교
초록
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.
키워드
Myocardial InfarctionHeparinBlood PlateletsPrognosisDRUG-ELUTING STENTSHIGH-RISK PATIENTSUNFRACTIONATED HEPARINRANDOMIZED-TRIALPLATELET-AGGREGATIONENOXAPARINSAFETYABCIXIMABEFFICACYOUTCOMES
식별자
- WoS UID
- 000284233100009
- KCI
- ART001492932



로그인
연구물 목록으로